Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. reports developments in genomic testing for rare disease diagnosis, with recurring updates on ExomeDx™ and GenomeDx™ testing, exome and genome test volumes, revenue growth, and full-year outlooks. The company uses GeneDx Infinity™, a rare disease genomic dataset, to support clinical interpretation, AI-enabled variant analysis, and biopharma discovery.
Company news also covers research publications and medical-meeting abstracts, health economics studies involving whole exome and whole genome sequencing, sponsored genetic testing programs for suspected rare diseases, and partnerships intended to expand access to genomic diagnosis. Updates frequently connect clinical data, sequencing technology, and rare disease patient identification with the company's precision-medicine operating model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
GeneDx (Nasdaq: WGS), a leader in genomic and clinical insights, has announced it will release its financial results for Q1 2023 on May 9, 2023, after market close. The event will include a conference call at 4:30 p.m. ET, hosted by President Katherine Stueland and CFO Kevin Feeley. Investors can register online to participate in the call, with both live and archived webcasts available on the GeneDx investor relations website.
GeneDx focuses on providing personalized health insights that inform diagnoses and treatment options, utilizing one of the largest rare disease data sets to support precision medicine. The company's efforts aim to enhance drug discovery and advance healthcare standards.
GeneDx (Nasdaq: WGS) announced the appointment of Devin K. Schaffer as General Counsel, effective April 24, 2023. Schaffer, with 15 years of legal experience, previously held leadership roles at Cardinal Health. As General Counsel, he will oversee all legal, compliance, and regulatory aspects for GeneDx. Katherine Stueland, President and CEO, expressed enthusiasm for Schaffer's addition to the executive leadership team, highlighting his ability to solve complex problems. His expertise aligns with GeneDx’s mission to enhance genomic insights and expand their healthcare offerings.
GeneDx Holdings Corp (Nasdaq: WGS) announced progress in the GUARDIAN study, which is screening 100,000 newborns for over 250 genetic conditions. To date, 1,000 newborns have been enrolled, with 2.6% showing true positive results for rare genetic disorders not part of standard newborn screening. The data presented at the ACMG Annual Meeting highlight the importance of whole genome sequencing (WGS) in early diagnosis, which could save approximately $30,000 per case by reducing unnecessary NICU care. GeneDx aims to make genomic sequencing a standard practice for newborn screening.